XENE vs. IDYA, CORT, ARWR, SMMT, BHVN, TGTX, MOR, RNA, FOLD, and RARE
Should you be buying Xenon Pharmaceuticals stock or one of its competitors? The main competitors of Xenon Pharmaceuticals include IDEAYA Biosciences (IDYA), Corcept Therapeutics (CORT), Arrowhead Pharmaceuticals (ARWR), Summit Therapeutics (SMMT), Biohaven (BHVN), TG Therapeutics (TGTX), MorphoSys (MOR), Avidity Biosciences (RNA), Amicus Therapeutics (FOLD), and Ultragenyx Pharmaceutical (RARE). These companies are all part of the "pharmaceutical preparations" industry.
IDEAYA Biosciences (NASDAQ:IDYA) and Xenon Pharmaceuticals (NASDAQ:XENE) are both mid-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, dividends, risk, institutional ownership, valuation, analyst recommendations, earnings, community ranking and media sentiment.
Xenon Pharmaceuticals received 294 more outperform votes than IDEAYA Biosciences when rated by MarketBeat users. Likewise, 69.39% of users gave Xenon Pharmaceuticals an outperform vote while only 67.86% of users gave IDEAYA Biosciences an outperform vote.
IDEAYA Biosciences has higher revenue and earnings than Xenon Pharmaceuticals. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than Xenon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
IDEAYA Biosciences currently has a consensus target price of $46.80, indicating a potential upside of 14.34%. Xenon Pharmaceuticals has a consensus target price of $59.11, indicating a potential upside of 49.42%. Given IDEAYA Biosciences' higher possible upside, analysts clearly believe Xenon Pharmaceuticals is more favorable than IDEAYA Biosciences.
In the previous week, IDEAYA Biosciences had 6 more articles in the media than Xenon Pharmaceuticals. MarketBeat recorded 12 mentions for IDEAYA Biosciences and 6 mentions for Xenon Pharmaceuticals. IDEAYA Biosciences' average media sentiment score of 0.55 beat Xenon Pharmaceuticals' score of 0.38 indicating that Xenon Pharmaceuticals is being referred to more favorably in the news media.
98.3% of IDEAYA Biosciences shares are owned by institutional investors. Comparatively, 95.5% of Xenon Pharmaceuticals shares are owned by institutional investors. 3.5% of IDEAYA Biosciences shares are owned by company insiders. Comparatively, 5.5% of Xenon Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Xenon Pharmaceuticals has a net margin of 0.00% compared to Xenon Pharmaceuticals' net margin of -483.05%. Xenon Pharmaceuticals' return on equity of -20.09% beat IDEAYA Biosciences' return on equity.
IDEAYA Biosciences has a beta of 0.83, suggesting that its share price is 17% less volatile than the S&P 500. Comparatively, Xenon Pharmaceuticals has a beta of 1.19, suggesting that its share price is 19% more volatile than the S&P 500.
Summary
Xenon Pharmaceuticals beats IDEAYA Biosciences on 9 of the 17 factors compared between the two stocks.
Get Xenon Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for XENE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding XENE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Xenon Pharmaceuticals Competitors List
Related Companies and Tools
